台股 » 個股 » 中裕 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

中裕

(4147)
可現股當沖
  • 股價
    87.9
  • 漲跌
    ▼2.2
  • 漲幅
    -2.44%
  • 成交量
    1,102
  • 產業
    上櫃 生技醫療類股
  • 321人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
中裕 (4147)籌碼相關-元大-竹北 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

Created with Highstock 1.3.7Zoom券商分點個股進出嗨投資 histock.tw05/0405/1806/0106/1406/2807/1207/2608/1008/2409/0609/2010/0410/1811/0211/1611/3012/1412/2801/1002/0402/1602/2603/1003/2004/0104/0380859095100105110May '24Jul '24Sep '24Nov '24Jan '25Mar '2560d90dAll

元大-竹北 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/04/02189.3000.0087.9012,2940.04%
2025/03/31290.10190.4088.0012,2770.04%
2025/03/28494.50493.8093.8002,2570.00%
2025/03/27696.92696.9096.1002,2480.00%
2025/03/26297.50298.4098.1002,2300.00%
2025/03/25298.20299.2098.6002,2100.00%
2025/03/24299.50299.0099.0002,1920.00%
2025/03/2100.00198.0096.40-12,149-0.05%
2025/03/180.191.6000.0091.900.12,0850.00%
2025/03/1700.00292.0091.90-22,077-0.10%
2025/03/14192.00292.9092.50-12,087-0.05%
2025/03/13391.33294.3591.6012,0990.05%
2025/03/12196.9000.0097.5012,0600.05%
2025/03/11295.30196.4095.6012,0410.05%
2025/03/10296.90295.6097.8002,0160.00%
2025/03/07297.95298.4096.5001,9910.00%
2025/03/050.197.9000.0098.600.11,9240.00%
2025/03/040.192.6000.0095.500.11,9040.01%
2025/03/030.194.4000.0094.200.11,8870.00%
2025/02/272.596.68295.5095.500.51,8780.03%
2025/02/26298.9500.0098.0021,8860.11%
2025/02/253100.833.1100.4399.30-0.11,856-0.01%
2025/02/243100.83399.9099.3001,7960.00%
2025/02/219101.89899.0598.9011,7270.06%
2025/02/2000.000.199.4099.70-0.11,553-0.01%
2025/02/190.195.5900.0095.200.11,5100.01%
2025/02/18094.00195.2094.00-11,491-0.07%
2025/02/1723101.8926.3102.1897.10-3.31,440-0.23%
2025/02/1400.00196.5098.90-11,226-0.08%
2025/02/1100.00192.2091.70-11,140-0.09%
2025/02/07089.0000.0090.1001,1250.00%
2025/02/05084.1000.0084.3001,1080.00%
2025/02/04084.6000.0083.3001,1140.00%
2025/01/2200.000.484.2084.90-0.41,116-0.04%
2025/01/210.184.8000.0084.500.11,1310.00%
2025/01/17185.5000.0084.6011,1310.09%
2025/01/13290.90391.0089.90-11,132-0.09%
2025/01/102.189.58188.8090.501.11,0640.10%
2025/01/09690.62187.8087.5051,0140.49%
2025/01/082100.502.1101.4997.20-0.1872-0.01%
2025/01/0700.0010.192.6992.70-10.1649-1.55%
2025/01/06290.400.190.1089.801.96110.31%
2025/01/03188.40188.4088.3006000.00%
2024/12/26085.8000.0086.3005920.00%
2024/12/19082.8300.0082.5006150.00%
2024/12/18082.9000.0082.9006260.00%
2024/12/17081.5000.0082.0006250.00%
2024/12/16081.9000.0081.8006310.00%
2024/12/13083.0000.0083.0006270.00%
2024/12/1000.00187.6087.50-1615-0.16%
2024/12/0900.000.587.6090.10-0.5600-0.08%
2024/12/06088.4000.0087.6005730.00%
2024/12/05085.6000.0085.0005270.00%
2024/12/0400.000.184.2085.30-0.1529-0.02%
2024/12/03084.8000.0084.3005290.00%
2024/11/29082.0000.0084.3005240.00%
2024/11/18079.10179.8078.70-1534-0.19%
2024/10/2900.00180.1080.90-1588-0.17%
2024/10/1700.00175.2075.00-1591-0.17%
2024/10/09174.1000.0073.9016220.16%
2024/10/01179.8000.0079.4016350.16%
2024/08/301.186.2700.0086.401.17500.15%
2024/08/280.184.3000.0083.700.17330.01%
2024/08/220.181.6000.0081.300.17590.01%
2024/08/2000.00180.0080.00-1754-0.13%
2024/08/0800.00176.7076.70-1783-0.13%
2024/08/0600.00270.2070.30-2771-0.26%
2024/08/051.674.3800.0074.001.67340.22%
2024/07/3100.00283.1082.60-2732-0.27%
2024/07/18188.6000.0088.4017090.14%
2024/07/171.288.2800.0088.101.27130.17%
2024/07/030.188.0000.0087.400.19530.01%
2024/07/020.188.80189.2088.60-0.9992-0.09%
2024/06/2400.00386.8386.70-31,128-0.27%
2024/05/31289.0000.0090.1021,4200.14%
2024/05/30189.1000.0088.6011,4750.07%
2024/05/24187.0000.0087.2011,8690.05%
2024/05/2100.00191.4088.00-12,123-0.05%
2024/04/3000.00085.1085.5002,3290.00%
2024/04/2200.002582.1281.80-252,329-1.07%
2024/04/1900.00183.6083.10-12,334-0.04%
2024/04/16188.0000.0087.9012,3510.04%
2024/04/1500.00890.6090.10-82,342-0.34%
2024/04/12194.1000.0094.0012,3390.04%
2024/04/1100.000.196.0095.80-0.12,3490.00%
2024/04/10396.07195.6093.2022,3390.09%
2024/04/09296.163.896.2596.20-1.72,301-0.07%
2024/04/08191.301.192.6293.00-0.12,2360.00%
中裕長效愛滋療法主要指標達標 啟動國際授權合作Anue鉅亨-8天前
中裕長效型愛滋療法2a臨床全數完成注射 今年底至明年初可獲初步結果Anue鉅亨-2024/08/30
中裕 相關文章
 
 
30小時47